Overview

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.

Eligibility

Inclusion Criteria:

1. Adults ≥18 years of age
2. Histologically confirmed relapsed/refractory SCLC, neuroendocrine cancer, malignant pleural mesothelioma, or synovial sarcoma
3. Measurable disease per RECIST v1.1 or mRECIST
4. ECOG performance status 0-1
5. Adequate hematologic, hepatic, renal, and coagulation function.
6. Life expectancy ≥12 weeks
7. Signed informed consent

Exclusion Criteria:

1. Active brain metastases
2. Major surgery or severe trauma within 4 weeks before first dose
3. Significant uncontrolled medical conditions preventing study participation
4. Use of prohibited concomitant medications
5. Previous conditions that would interfere with study assessments or safety